The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
September 7th 2024
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
The Consistent Benefits of Continued Glucose Monitoring in Type 1 Diabetes Patients
The DIaMonD and GOLD Studies, which used continued glucose monitoring (CGM) in patients with type 1 diabetes who were in less than optimal control showed that the addition of CGM to these patients’ self-monitoring of blood glucose contributed to lower A1C, more time spent in range, less hypoglycemia, less severe hyperglycemia, and better quality of life.
Diabetes: Definition of High BMI Differs Between Americans and Asians
April 1st 2017For Americans, a BMI of 25 means they are overweight. However, a BMI of 23.5 means overweight for Asians. David O’Dell, MD, of the University of Nebraska Medical Center explains why this matters at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.
Hypogonadism, Diabetes: Chronic Diseases That Need to be Treated For Life
The type 1 diabetes patients who were continuously administered testosterone treatment showed improvements in glycemic control as well as massive improvements in their weight loss, since testosterone increases lean body mass.
Long-Term Testosterone Therapy: Effects on Hypogonadal Men with Type 1 Diabetes
Farid Saad, DVM, PhD, Bayer Pharma AG learned that the men with type 1 diabetes did experience benefits of long-term testosterone therapy – they showed improvements in their underlying diseases.
It Takes a Team to Build Personalized Care for Type 2 Diabetes
March 30th 2017Diana McNeill, MD, of Duke University Medical Center moderated a panel at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California. The topic of discussion? Personalized care in type 2 diabetes.